LOS ANGELES, April 4, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the independent Data Safety Monitoring Board (DSMB) of the Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial has completed its pre-specified review of the first patient cohort. Based on the DSMB's recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor's lead product candidate, in boys with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
"The DSMB's recommendation to proceed with enrollment in the HOPE-Duchenne clinical trial is encouraging, and confirms our initial understanding of the safety of CAP-1002 in the DMD patient population, which is an important step toward establishing a potential new treatment to help these boys. In addition, the DSMB's recommendation reassures us with respect to the safety of the catheter procedure for the administration of CAP-1002 for these potential trial participants," said Linda Marbán, Ph.D., president and chief executive officer of Capricor Therapeutics. "With heart disease being one of the primary drivers of death and disability in older DMD patients, each step we take toward better managing DMD is an important one. We look forward to sharing additional milestones from the HOPE-Duchenne trial in the coming months, including its top-line results, which are expected in the first quarter of 2017."
CAP-1002 is an allogeneic, intracoronary-delivered, cardiosphere-derived cell treatment. This investigational "off-the-shelf" cell therapy is derived from donor heart tissue and is infused directly into the coronary arteries by catheter. CAP-1002 has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of DMD.
In February 2016, Capricor announced that the first patient had been treated in the HOPE-Duchenne clinical trial. This multi-center, randomized, open-label, usual care-controlled study is designed to evaluate the safety and preliminary efficacy of CAP-1002 in 24 male patients with DMD who have significant cardiac involvement. The first patient cohort consisted of six patients.
About Duchenne Muscular Dystrophy (DMD)
DMD is a rare, genetic disorder of muscle and afflicts approximately 20,000 boys and young men in the U.S. It results from an inherited abnormality in the dystrophin complex, leading to progressive damage to skeletal and cardiac muscle. No treatment has been approved for the treatment of DMD, and nearly all of the candidates in development are directed toward improving skeletal muscle. However, heart disease is the leading cause of death in DMD patients despite optimal medical therapy, and virtually all DMD patients 15 years of age and older develop heart failure. Heart transplantation is not generally an option for those with DMD.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Capricor's lead programs target post myocardial infarction (heart attack), heart failure and Duchenne muscular dystrophy. Capricor has two lead product candidates under clinical investigation: CAP-1002, a cardiac cell therapy, and Cenderitide, a dual natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as other potential indications. In addition, Capricor is conducting research and development on its exosomes platform technology for cardiac diseases and other therapeutic areas. For additional information, visit www.capricor.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offering and the anticipated effects of the offering, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business are set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 30, 2016, and in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
For more information, please contact:
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance
SOURCE Capricor Therapeutics, Inc.